Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Forestalling BRAF-Inhibitor Resistance in a Shocking Way.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2018

Sullivan Ryan J

Abstract excerpt

Targeting BRAF in BRAF-mutant melanoma is highly effective, but most patients develop resistance. HSP90 has been implicated and identified as a therapeutic target. Ultimately, early-stage clinical investigation will be necessary to provide proof of principle of this approach and if appropriate randomized trials to confirm promising findings. Clin Cancer Res; 24(22); 5496-8. ©2018 AACR See related article by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm
Share to BRAF gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 29980533
DOI: 10.1158/1078-0432.CCR-18-1344

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Forestalling BRAF-Inhibitor Resistance in a Shocking Way.PMID 29980533Read ↗

HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.Semantic proximity Read ↗

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.Semantic proximity Read ↗

RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.Semantic proximity Read ↗

Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma.Semantic proximity Read ↗

Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.Semantic proximity Read ↗

Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.Semantic proximity Read ↗

Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors.Semantic proximity Read ↗

Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma.Semantic proximity Read ↗

Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling.Semantic proximity Read ↗

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.Semantic proximity Read ↗

Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.Semantic proximity Read ↗

A new BRAF inhibitor breaks resistance barriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.